Dr. Reckamp Discusses Heat Shock Proteins in Lung Cancer

Karen Reckamp, MD
Published: Wednesday, Aug 17, 2011

Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, discusses the use of heat shock proteins in the treatment of lung cancer.

Reckamp explains that heat shock proteins act as chaperone proteins that permit oncoproteins to function. The proteins work as an alternative to inhibiting the tyrosine kinase pathway and are involved in multiple lung cancer related signalling pathways such as EGFR, RAS, ALK, and MET. Heat shock proteins can be used when resistance to other methods are developed.
Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, discusses the use of heat shock proteins in the treatment of lung cancer.

Reckamp explains that heat shock proteins act as chaperone proteins that permit oncoproteins to function. The proteins work as an alternative to inhibiting the tyrosine kinase pathway and are involved in multiple lung cancer related signalling pathways such as EGFR, RAS, ALK, and MET. Heat shock proteins can be used when resistance to other methods are developed.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x